-
公开(公告)号：US10457735B2
公开(公告)日：2019-10-29
申请号：US15538419
申请日：2016-01-08
Applicant: BIONTECH AG , GENMAB A/S
Inventor： Ugur Sahin , Friederike Gieseke , Isil Altintas , David Satijn , Paul Parren
IPC: C07K16/28
Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
-
公开(公告)号：US20180194849A1
公开(公告)日：2018-07-12
申请号：US15538419
申请日：2016-01-08
Applicant: BIONTECH AG , GENMAB A/S
Inventor： Ugur Sahin , Friederike Gieseke , Isil Altintas , David Satijn , Paul Parren
IPC: C07K16/28
Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
-
公开(公告)号：US20240392032A1
公开(公告)日：2024-11-28
申请号：US18617483
申请日：2024-03-26
Applicant: Genmab A/S
Inventor： David SATIJN , Esther C.W. Breij , Bart E.C.G. De Goeij , Kristel Kemper , Patrick Engelberts , Edward N. Van Den Brink , Rik Rademaker , Dennis Verzijl , Sjeng Horbach , Paul Parren
Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
-
公开(公告)号：US20230374131A1
公开(公告)日：2023-11-23
申请号：US18109708
申请日：2023-02-14
Applicant: Genmab A/s
Inventor： Edward Norbert VAN DEN BRINK , Joost J. Neijssen , Aran Frank Labrijn , Joyce Meesters , Janine Schuurman , Isil Altintas , Paul Parren , Rik Rademaker
CPC classification number: C07K16/2809 , C07K16/2887 , C07K16/32 , C07K16/1063 , C07K16/2863 , C07K16/2896 , C07K16/4241 , G01N33/6872 , A61K2039/505
Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
-
公开(公告)号：US11814411B2
公开(公告)日：2023-11-14
申请号：US17144591
申请日：2021-01-08
Applicant: BIONTECH SE , GENMAB A/S
Inventor： Ugur Sahin , Friederike Gieseke , Isil Altintas , David Satijn , Paul Parren
IPC: C07K16/28
CPC classification number: C07K16/2878 , C07K2317/31 , C07K2317/565 , C07K2317/75 , C07K2317/92
Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
-
Patent Agency Ranking
公开(公告)号：US11046771B2
公开(公告)日：2021-06-29
申请号：US15832366
申请日：2017-12-05
Applicant: GENMAB A/S
Inventor： Bart De Goeij , Simone De Haij , Thilo Riedl , Rene Hoet , Ole Baadsgaard , Jan Van De Winkel , David Satijn , Paul Parren , Aran Frank Labrijn , Joyce Meesters , Janine Schuurman , Edward N. Van Den Brink
Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
-
公开(公告)号：US10906991B2
公开(公告)日：2021-02-02
申请号：US14934956
申请日：2015-11-06
Applicant: GENMAB A/S
Inventor： Janine Schuurman , Tom Vink , Jan Van De Winkel , Aran Frank Labrijn , Rob Aalberse , Marijn Van Der Neut Kolfschote , Paul Parren
Abstract: The invention relates to an ex vivo method for the generation of a bispecific antibody, comprising the steps of: a) providing a first antibody having a first binding specificity, wherein said first antibody comprises an IgG4-like CH3 region, b) providing a second antibody having a second binding specificity which differs from said first binding specificity, wherein said second antibody comprises an IgG4-like CH3 region, c) incubating said first and second antibodies together under reducing conditions which allow the cysteines in the core hinge region to undergo disulfide-bond isomerization, and d) obtaining a bispecific antibody. The invention furthermore relates to bispecific antibodies obtainable by the method of the invention.
-
公开(公告)号：US20190169311A1
公开(公告)日：2019-06-06
申请号：US15998816
申请日：2018-08-16
Applicant: Genmab A/S
Inventor： Sandra Verploegen , David P.E. Satijn , Rene M.A. Hoet , Paul Parren , Jan Van De Winkel , Vibeke Miller Breinholt , Eva Ehrnrooth , Ole Baadsgaard , Tom Vink , Willem Karel Bleeker , Mischa Houtkamp , Maroeska Oudshoorn , Rob N. De Jong
IPC: C07K16/36 , A61K39/395
Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
-
公开(公告)号：US20180319888A1
公开(公告)日：2018-11-08
申请号：US15977725
申请日：2018-05-11
Applicant: Genmab A/S
Inventor： Aran Frank Labrijn , Stefan Loverix , Paul Parren , Jan Van De Winkel , Janine Schuurman , Ignace Lasters
IPC: C07K16/28 , C07K16/00 , A61K47/68 , A61K51/10 , A61K39/395
CPC classification number: C07K16/2863 , A61K39/3955 , A61K47/6849 , A61K51/103 , A61K2039/505 , C07K16/00 , C07K2317/21 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/76
Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.
-
公开(公告)号：US20150376282A1
公开(公告)日：2015-12-31
申请号：US14739768
申请日：2015-06-15
Applicant: Genmab A/S
Inventor： Aran Frank Labrijn , Stefan Loverix , Paul Parren , Jan Van De Winkel , Janine Schuurman , Ignace Laster
IPC: C07K16/28 , A61K47/48 , A61K51/10 , A61K39/395
CPC classification number: C07K16/2863 , A61K39/3955 , A61K47/6849 , A61K51/103 , A61K2039/505 , C07K16/00 , C07K2317/21 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/76
Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.
Abstract translation: 本发明涉及抗体的恒定区，特别是IgG4的CH3区的位置，其影响了CH3-CH3相互作用的强度。 公开了稳定或不稳定这种相互作用的突变。
-
-
-
-
-
-
-
-
-
Search Results
64
records
(took 0.037 seconds)
